Eli Lilly and Co Analyst Ratings
Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Goldman Sachs raised the target price of Eli Lilly and Co. to $793.
BMO Capital Maintains Outperform on Eli Lilly and Co, Maintains $1001 Price Target
Goldman Sachs Adjusts Price Target on Eli Lilly & Co. to $793 From $785, Maintains Neutral Rating
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Jefferies Financial raised the target price of Eli Lilly and Co. to $1015.
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings